DeutschNewstral
Article
jdsupra.com on 2015-08-31 19:49
Amgen and Apotex do the Biosimilar Patent Dance
Related news
- Amgen v. Apotex – what is the outcome when biosimilar applicants actually dance?jdsupra.com
- Federal Circuit Provides Guidance on Statements in Patent Dance Letters and Sunovion in Amgen v Apotexjdsupra.com
- Amgen v. Sandoz Biosimilar Litigation Update: Sandoz Follows the Patent Dance With Neulastajdsupra.com
- Supreme Court Defers Certiorari Decision In Amgen Sandoz Biosimilar Patent Dance Disputejdsupra.com
- Apotex Follows the BPCIA “Patent Dance” Againjdsupra.com
- Court Rules that Apotex Must Give Amgen Notice Upon Biosimilar Licensurejdsupra.com
- The Ripple Effect of the Federal Circuit’s Decision in Amgen v. Apotex on Biosimilar Litigationjdsupra.com
- Supreme Court Will Judge Biosimilar Patent Dancejdsupra.com
- Amgen Files New Patent Infringement Suit Over Neupogen Biosimilarjdsupra.com
- Amgen DJ to Compel Patent Dance Dismissedjdsupra.com
- No Rehearing Of Biosimilar Patent Dance Decisionjdsupra.com
- Federal Circuit Decides Amgen v. Apotex, Holds that 180-Day Notice of Commercial Marketing is Always Mandatory in Biosimilar Litigationjdsupra.com
- Apotex Takes Aim at Amgen Patent in IPR Petition After Being Sued Under the BPCIAjdsupra.com
- How Will The Supreme Court Choreograph The Biosimilar Patent Dance?jdsupra.com
- Will You, Won't You Join The Biosimilar Patent Dance?jdsupra.com
- Will The Avastin Biosimilar Patent Dance Go On?jdsupra.com
- New Guidance on Mandatory Notice in the Biosimilar ‘Patent Dance’jdsupra.com
- Biosimilar Remedies Not Limited Without Full Patent Dancejdsupra.com
- Remicade Biosimilar Closer To Approval, But Patent Dance Goes Onjdsupra.com
- Amgen Sues Pfizer and Hospira for Patent Infringement related to Hospira’s Filgrastim Biosimilarjdsupra.com